Pharnext Presents a Business Update Webcast on May 20th, 2020

PARIS, FRANCE / ACCESSWIRE / May 14, 2020 / Pharnext SA (FR0011191287 – ALPHA), an advanced clinical-stage biopharmaceutical company pioneering a new approach to developing innovative drug combinations based on big genomic data and artificial intelligence, today confirmed the organization of a webcast to update on its current activities on May 20th, 2020 at 6:00 pm (CET).

During this webcast, David Horn Solomon, Chief Executive Officer, will provide a business update and overview of Pharnext.

Attendees can participate by weblink: https://channel.royalcast.com/webcast/pharnext/20200520_1/ or connect by phone using the following coordinates:

Confirmation Code: Pharnext

Dials-in:
– USA: +1 212 999 6659
– France: +33 (0) 1 7099 4740
– UK: +44 (0) 20 3003 2666

About Pharnext

Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for orphan and common neurodegenerative diseases that currently lack curative and/or disease-modifying treatments. Pharnext has two lead products in clinical development. PXT3003 completed an international Phase 3 trial with positive topline results for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated encouraging Phase 2 results in Alzheimer’s disease. Pharnext has developed a new drug discovery paradigm based on big genomic data and artificial intelligence: PLEOTHERAPY(TM). Pharnext identifies and develops synergic combinations of drugs called PLEODRUG(TM). The Company was founded by renowned scientists and entrepreneurs, including Professor Daniel Cohen, pioneer in modern genomics, and is supported by a world-class scientific team. More information at www.pharnext.com.

Pharnext is listed on the Euronext Growth Stock Exchange in Paris (ISIN code: FR0011191287).

Contacts: 

Pharnext
David Solomon
Chief Executive Officer
contact@pharnext.com
+33 (0)1 41 09 22 30
     

Media Relations (Europe)
Ulysse Communication
Bruno Arabian
+33 (0)6 87 88 47 26
barabian@ulysse-communication.com

Pierre-Louis Germain
+33 (0)6 64 79 97 51
plgermain@ulysse-communication.com
+33 (0)1 81 70 96 30

Financial Communication (France)
Actifin
Stéphane Ruiz
sruiz@actifin.fr
+33 (0)1 56 88 11 15

Investors Relations (U.S.)
Stern Investor Relations, Inc.
Jane Urheim
jane.urheim@sternir.com
+1 212 362 1200


SOURCE: Pharnext via EQS Newswire

View source version on accesswire.com:
https://www.accesswire.com/589896/Pharnext-Presents-a-Business-Update-Webcast-on-May-20th-2020

Staff

Recent Posts

The Leadership Shift Powering Doceree’s Next Chapter in the US: Kamya Elawadhi Announced as Co-Founder & President

Strategic elevation signals bold expansion as Doceree redefines healthcare marketing with AI-powered precision and purposeSHORT…

58 minutes ago

Canvas Medical Named 2026 Best in KLAS for Ambulatory Specialty EHR

Next-generation EMR platform recognized for helping specialty practices deliver efficient, personalized patient careSAN FRANCISCO, Feb.…

58 minutes ago

Kontakt.io Introduces Supply Chain AI to Transform Care Support Operations

Agentic AI integrates EHR and RTLS data to automate equipment workflows and improve operational efficiency,…

58 minutes ago

Robotic Surgery Market Is No Longer a Technology Story. It Is a Discipline Test for Hospitals: MMR Statistics

PUNE, India, Feb. 4, 2026 /PRNewswire/ -- For nearly a decade, robotic surgery was sold as progress.…

58 minutes ago

Champion Insights Officially Opens Enrollment to Investigate ALS Risk in High-Performance Athletes, Military Members, and First Responders

Ambitious nationwide study will enroll 500 participants to examine genetic, biological, and environmental factors linked…

58 minutes ago

WTWH Media Announces 2025 Prism Award Winners

CLEVELAND, Feb. 4, 2026 /PRNewswire/ -- WTWH Healthcare, a WTWH Media, LLC company, is proud…

58 minutes ago